quantisnow
FeedTopReportsPricing
⌘K
Live feed
04:39:18·577d
FDARegulatory
Sanofi logo

FDA Approval for FEXINIDAZOLE issued to SANOFI

SNY· Sanofi
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • SNY
    Sanofi
    Health Care

Recent analyst ratings

  • Apr 20UpdateBNP Paribas Exane$50.00
  • Feb 12UpdateBofA Securities-
  • Jan 27UpdateCitigroup-
  • Jan 16UpdateUBS-
  • Jan 6UpdateBarclays-
  • Dec 9UpdateGuggenheim-

Related

  • SEC14h
    SEC Form 6-K filed by Sanofi
  • ANALYST3d
    Sanofi downgraded by BNP Paribas Exane with a new price target
  • SEC8d
    SEC Form 6-K filed by Sanofi
  • PR14d
    Sanofi becomes market authorization holder for Nuvaxovid® in Canada, expanding COVID-19 vaccine choices for Canadians
  • SEC23d
    SEC Form 6-K filed by Sanofi
  • SEC30d
    SEC Form 6-K filed by Sanofi
  • SEC44d
    SEC Form 6-K filed by Sanofi
  • SEC50d
    SEC Form 6-K filed by Sanofi
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022